As part of the Agios deal Servier also took rights to vorasidenib – a dual inhibitor of mutated IDH1 and IDH2 – that is in trials for a hard-to-treat form of brain cancer called glioma.

Privately-held French drugmaker Servier has announced the appointment of Nitza Thomasson as executive director, R&D Neurology.

Servier is already in the process of transforming itself into a much bigger player in cancer, and has just tripled its sales objectives for the category. Fresh with a new brand identity ...

The pharma company Servier sponsored the clinical trials for the drug and will bring it to market. What it does: The ...

He is currently Executive Director Research at Servier, where he manages the research centers in France, Denmark, Hungary and ...

Servier and The World Heart Federation (WHF) have announced that the duo has taken the lead in rallying support from ...

Egypt - Servier Egypt, part of the global Servier Group, has commemorated its 70th anniversary with the opening of a new production line and the launch of the “Access Cancer Treatment (ACT) for ...

This year’s campaign, #DontMissaMoment, tackles widespread non-adherence, which leads to worsening health outcomes, unnecessary hospitalisations, and rising healthcare costs. The World Heart ...